Alembic seeks to mix it with US and European players
Alembic seeks to mix it with US and European players Indian pharmaceutical firm Alembic is seeking to expand its presence in the lucrative US and European drug markets through an expanded partnering programme. The Gujarat-headquartered group, which is involved in both the active pharmaceutical ingredient (API) and pharmaceutical formulation markets, aims to grow internationally and double its annual turnover over the next two to three years, according to a report in India’s Business Standard. Company director Pranav Amin explained that the firm intends to file about 10-12 ANDAs every year and to tap potential in the generic markets of the US and Europe. The company has also submitted around 22 drug master file (DMF) requests to regulatory agencies in Europe and the US in recent years in a bid to boost its roster of API clients.